As per MRFR analysis, the US Needle Biopsy Market Size was estimated at 470.4 (USD Million) in 2023. The US Needle Biopsy Market Industry is expected to grow from 491.4 (USD Million) in 2024 to 885.65 (USD Million) by 2035. The US Needle Biopsy Market CAGR (growth rate) is expected to be around 5.501% during the forecast period (2025 - 2035).
The US Needle Biopsy Market is seeing significant trends driven by advancements in technology and the increasing prevalence of cancer. The introduction of minimally invasive biopsy techniques is one of the key market drivers, as these methods significantly reduce patient recovery time and associated risks, making them more favorable for both healthcare providers and patients. Moreover, the growth in the geriatric population in the US is increasing the demand for diagnostic procedures like needle biopsies, as older individuals are more susceptible to cancer and other chronic diseases.
Opportunities in the US market are notable with the ongoing development of innovative biopsy devices and techniques that enhance precision and accuracy. The rise of image-guided biopsies, including ultrasound and CT-guided procedures, is particularly significant as these methods improve diagnostic confidence and streamline clinical workflows. Also, there is potential growth in telemedicine, which allows for remote consultations and follow-ups related to biopsy procedures, improving patient accessibility and satisfaction.
Recent trends indicate a shift toward personalized medicine, where needle biopsy plays a crucial role in tumor profiling and treatment decision-making. As molecular diagnostics gain traction, the capabilities of needle biopsies are expanding, enabling oncologists to tailor therapies based on the specific characteristics of tumors. Furthermore, the integration of artificial intelligence in pathology to analyze biopsy samples is on the rise, enhancing diagnostic accuracy and operational efficiency. Overall, the US Needle Biopsy Market is on an upward trajectory supported by technological innovations and evolving healthcare demands.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising incidence of cancer in the United States is a significant driver for the US Needle Biopsy Market Industry. According to the American Cancer Society, it is projected that there will be approximately 1.9 million new cancer cases diagnosed in the year 2021 alone, with breast, lung, prostate, and colorectal cancers accounting for a large portion of these cases. This alarming statistic highlights the urgent need for diagnostic procedures like needle biopsy, which is essential for accurate cancer diagnosis and staging.
Furthermore, the National Cancer Institute indicates that more advanced needle biopsy techniques are becoming increasingly important due to their ability to provide less invasive options for obtaining tissue samples. As the prevalence of cancer continues to rise, this trend is expected to drive growth within the US Needle Biopsy Market, enhancing the demand for various types of needle biopsy devices and services, facilitating early detection, and ultimately improving patient outcomes.
Technological advancements are another crucial driver for the US Needle Biopsy Market Industry. The development of innovative devices such as automated biopsy systems, imaging-guided biopsy techniques, and advancements in needle design have significantly improved the accuracy and efficiency of needle biopsies. For example, multiple organizations, including the American Society of Clinical Oncology, have endorsed the use of Ultrasound and CT-guided biopsy techniques due to their lower complication rates and higher diagnostic accuracy.
The ability to streamline procedures and reduce patient discomfort not only enhances the overall biopsy experience but also increases the adoption of needle biopsy processes in outpatient settings. With continuous Research and Development efforts from major players in the medical device market, such as Boston Scientific and Medtronic, the industry is likely to see ongoing innovation, further driving market growth over the coming years.
Increasing awareness of the importance of early diagnosis among patients and healthcare providers significantly elevates the demand for needle biopsy procedures in the US Needle Biopsy Market Industry. Organizations such as the Centers for Disease Control and Prevention (CDC) have been actively promoting cancer screening and early detection initiatives, resulting in more individuals seeking diagnostic procedures when experiencing potential symptoms.
With government campaigns and educational programs urging people to be proactive about their health, the number of patients seeking needle biopsies is expected to rise. A growing patient population recognizing the essential role of timely interventions and the importance of following recommended screening guidelines will consequently enhance the adoption of needle biopsy procedures, fostering market growth in the United States.
The US Needle Biopsy Market encompasses various types, each serving distinct applications in the medical field. A prominent type is Fine Needle Aspiration Biopsy (FNAB), which is widely adopted due to its minimally invasive nature. This method enables the extraction of cellular material from lesions and masses for cytological examination, making it an essential tool in oncology for rapid diagnosis and treatment planning. Its efficiency and relatively low complication rate contribute to its significant presence in the market, catering to patients who require quick and less painful procedures.
Core Needle Biopsy serves as another vital component of the US Needle Biopsy Market. It typically involves the use of a larger needle compared to FNAB and allows for the extraction of a tissue sample, providing more substantial information for histopathological analysis. This type is particularly significant when deeper or larger samples are necessary, which is often the case in breast or prostate biopsies. As the healthcare industry increasingly leans towards precise and effective diagnostic techniques, Core Needle Biopsy stands out due to its accuracy and the ability to provide comprehensive information on tissue architecture.
Vacuum-Assisted Biopsy (VAB) is also gaining prominence in the US Needle Biopsy Market. This technique utilizes a vacuum mechanism to remove multiple tissue samples in a single insertion, often leading to fewer complications and less patient discomfort. VAB is especially beneficial for breast biopsies, allowing for a more extensive examination of suspicious areas without the need for multiple needle insertions. As advances in technology continue to enhance procedural efficiency, the importance of Vacuum-Assisted Biopsy is expected to rise.
Trends in the US healthcare sector are leaning towards minimally invasive procedures, thereby driving the growth of these various types of needle biopsies. An increased focus on early detection and screening, especially for conditions like cancer, is propelling the demand for these procedures. Furthermore, the rise in awareness among patients and healthcare professionals regarding the benefits of needle biopsy techniques is significantly influencing market dynamics. Overall, the segmentation within the US Needle Biopsy Market reflects a diverse landscape where innovations in technique and technology profoundly impact patient outcomes and healthcare practices.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Application segment of the US Needle Biopsy Market plays a crucial role in facilitating precise diagnostic and therapeutic procedures, covering vital areas such as Oncology, Cardiology, Gastroenterology, and Pulmonology. Oncology holds a particularly significant position within this market, driven by the increasing incidence of cancer and the demand for early detection methods to improve patient survival rates. Cardiology is becoming increasingly relevant as needle biopsies enable minimally invasive procedures for diagnosing heart conditions.
Gastroenterology benefits from needle biopsies for assessing liver diseases and gastrointestinal tract disorders, significantly enhancing patient management. In Pulmonology, the importance of needle biopsy procedures has surged, especially with the rising prevalence of respiratory disorders, allowing for effective tissue sampling from lung lesions. The market is anticipated to experience growth due to trends focusing on minimally invasive techniques and enhancements in diagnostic accuracy. Additionally, the demand for advanced imaging technologies and the increasing interest in personalized treatment options are further driving the focus within these applications in the US Needle Biopsy Market. Overall, the segmentation within the application area underpins significant advancements in patient care and treatment strategies across various medical fields.
The Guidance Technique segment of the US Needle Biopsy Market plays a pivotal role in enhancing diagnostic accuracy and procedural efficiency. This segment includes techniques such as Ultrasound Guided, CT Guided, and Mammography Guided biopsies, each offering unique benefits that cater to different clinical needs. Ultrasound Guided biopsies are widely regarded for their real-time imaging capabilities, allowing for precise needle placement, thereby minimizing patient discomfort and improving specimen quality. CT Guided techniques are particularly valued for their effectiveness in targeting lesions that are not easily accessible, making them crucial in various oncological applications.
Meanwhile, Mammography Guided biopsies are essential for targeting suspicious breast tissue, ensuring that the correct area is sampled for accurate diagnosis. The significance of these techniques within the US Needle Biopsy Market is underscored by the increasing incidence of cancer diagnoses and the growing emphasis on minimally invasive procedures. As technological advancements continue to evolve, the adoption of these guidance techniques is expected to enhance patient outcomes and streamline workflows in healthcare settings. Overall, the focus on precise and efficient biopsy procedures in the US drives innovative solutions and expands the capabilities of healthcare professionals in diagnostic medicine.
The US Needle Biopsy Market, particularly within the End Use segment, showcases a robust landscape consisting of various vital components that are integral to healthcare delivery. Hospitals play a crucial role as primary providers of needle biopsy procedures, ensuring that patients receive timely diagnostics for conditions such as cancer. The emphasis on rapid and accurate diagnosis has bolstered the demand for such procedures, making hospitals a dominant force in this segment. Diagnostic Laboratories also significantly contribute to this market, serving as specialized centers that enhance the precision and reliability of biopsy analyses, which is critical for effective patient treatment plans.
Additionally, Research Institutions are essential as they drive innovation and development within the needle biopsy field, focusing on enhancing techniques and technologies that improve accuracy and patient outcomes. Overall, the interplay between these three key areas underscores the importance of the End Use segment in the US Needle Biopsy Market, facilitating advancements in medical technology while addressing patient care needs efficiently. The growth in this segment is also supported by the increasing prevalence of chronic diseases and the rising emphasis on early diagnosis.
The US Needle Biopsy Market is a dynamic segment characterized by rapid advancements in medical technology and increasing demand for minimally invasive procedures. This market encompasses a variety of biopsy tools and systems designed for tissue collection, essential for accurate diagnosis in oncology and other medical fields. As the market continues to expand, driven by an aging population and rising incidence rates of diseases requiring biopsy procedures, competition among key players intensifies. Companies are focusing on innovation, product differentiation, and strategic partnerships to enhance their market position. The competitive landscape reveals a mix of established entities and emerging firms, all striving to capture share in this lucrative market, leading to a robust environment marked by ongoing technological innovations and regulatory advancements.
Devicor Medical Products holds a strong presence in the US Needle Biopsy Market, recognized for its commitment to high-quality biopsy solutions tailored for healthcare providers. The company specializes in advanced device development aimed at improving patient outcomes through precision and efficiency. Devicor Medical Products differentiates itself with its user-friendly devices that facilitate faster procedures and reduce the risk of complications. Its innovative approach, combined with a focus on comprehensive training and support for medical professionals, positions the company favorably within the market. By continually investing in research and development, Devicor Medical Products strengthens its portfolio, harnessing the latest technologies and positioning itself as a leader in the needle biopsy sector within the United States.
Hologic is another significant player in the US Needle Biopsy Market, renowned for its comprehensive range of diagnostic solutions. The company provides a suite of key products and services including advanced imaging systems and innovative biopsy devices, which cater to various clinical needs in breast health and interventions. Hologic leverages its strong market presence through strategic mergers and acquisitions, enhancing its capabilities and expanding its product offerings. The integration of cutting-edge technology and a commitment to quality allows Hologic to maintain a competitive edge. Furthermore, the company emphasizes partnerships with medical professionals, ensuring that its product solutions meet the evolving demands of healthcare facilities across the US. With a focus on innovation and high-performance products, Hologic continues to make significant strides in the needle biopsy arena, reinforcing its reputation as a trusted partner in enhancing patient care.
The US Needle Biopsy Market has been increasingly dynamic in recent months, showcasing significant innovations and developments. In September 2023, Devicor Medical Products announced enhancements to its biopsy platform, improving precision in targeting lesions, which is expected to impact diagnostic accuracy positively. Meanwhile, Hologic expanded its portfolio with new biopsy systems tailored for breast cancer diagnostics, indicating a shift towards advanced technologies aimed at improving patient outcomes. Market demands are also evident with Boston Scientific's new partnerships to integrate advanced imaging techniques into their biopsy devices, thereby enhancing procedural efficiency.
Additionally, there have been notable movements in the corporate landscape, with Medtronic acquiring a niche player in the biopsy market in August 2023, which is aimed at broadening its product offerings. The overall market has seen consistent growth, with 2022 valuations reported at approximately USD 3 billion, and projections suggesting a compound annual growth rate of over 5% through 2028, underlining the potential for innovative biopsy solutions to address rising healthcare needs in the US. As companies like Ethicon and Cook Medical refine their strategies, competitive dynamics within the US Needle Biopsy Market continue to evolve robustly.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 470.4(USD Million) |
| MARKET SIZE 2024 | 491.4(USD Million) |
| MARKET SIZE 2035 | 885.65(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.501% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Devicor Medical Products, Hologic, Radi Medical, Boston Scientific, Medtronic, TruCorp, Transluminal Technologies, Olympus Corporation, Cardinal Health, Cook Medical, Biopsy Sciences, Ethicon, Zimmer Biomet, Acist Medical Systems, BD |
| SEGMENTS COVERED | Type, Application, Guidance Technique, End Use |
| KEY MARKET OPPORTUNITIES | Expanding diagnostics in oncology, Increasing demand for minimally invasive procedures, Technological advancements in needle devices, Rising prevalence of chronic diseases, Growing awareness and education initiatives |
| KEY MARKET DYNAMICS | growing demand for minimally invasive procedures, increasing prevalence of cancer, advancements in imaging technology, rising adoption of outpatient procedures, supportive reimbursement policies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Needle Biopsy Market is projected to be valued at 491.4 million USD in 2024.
By 2035, the US Needle Biopsy Market is expected to reach a value of 885.65 million USD.
The expected CAGR for the US Needle Biopsy Market from 2025 to 2035 is 5.501 percent.
The Core Needle Biopsy segment is expected to dominate, with a value of 200.0 million USD in 2024.
The Fine Needle Aspiration Biopsy segment is anticipated to reach 270.0 million USD by 2035.
Major players in the US Needle Biopsy Market include Hologic, Boston Scientific, and Medtronic, among others.
The Vacuum-Assisted Biopsy segment is valued at 141.4 million USD in 2024.
Challenges include increasing competition and the need for technological advancements in biopsy procedures.
Rising prevalence of cancer and advancements in biopsy techniques are significant growth drivers in the market.
The Core Needle Biopsy segment is expected to experience significant growth, reaching 360.0 million USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
